Our Science – Franchini Website

Genoveffa Franchini, M.D.

Selected Publications

1) Cecchinato V, Trindade CJ, Laurence A, Heraud JM, Brenchley J, Tryniszewska E, Ferrari MG, Tsai W, Vaccari M, Washington-Parks R, Venzon D, Douek DC, O'Shea JJ, Franchini G.
Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques.
Mucosal Immunology. 279–288, 2008. [Journal]

2) Vaccari M, Boasso A, Ma Z, Cecchinato V, Venzon D, Doster M, Tsai W, Shearer G, Fuchs D, Felber B, Pavlakis G, Miller J, Franchini G.
CD4+ T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIVmac251 infection.
Mucosal Immunology. Online, 2008. Full Text Article. [Journal]

3) Kaufman DR, Goudsmit J, Holterman L, Ewald BA, Denholtz M, Devoy C, Giri A, Grandpre LE, Heraud JM, Franchini G, Seaman MS, Havenga MJ, Barouch DH.
Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
J. Virol. 82: 6829-37, 2008. [Journal]

4) Cecchinato V, Tryniszewska E, Ma ZM, Vaccari M, Boasso A, Tsai WP, Petrovas C, Fuchs D, Heraud JM, Venzon D, Shearer GM, Koup RA, Lowy I, Miller CJ, Franchini G.
Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection.
J. Immunol. 180: 5439-47, 2008. [Journal]

5) Fukumoto R, Andresen V, Bialuk I, Cecchinato V, Walser JC, Valeri VW, Nauroth JM, Gessain A, Nicot C, Franchini G.
In vivo genetic mutations define predominant functions of the human T-cell leukemia/lymphoma virus p12I protein.
Blood. 2008. [Journal]

6) Vaccari M, Mattapallil J, Song K, Tsai W, Hryniewicz A, Venzon D, Zanetti M, Reimann KA, Roederer M, Franchini G.
Reduced Protection From SIVmac251 Afforded by Memory CD8+ T-cells Induced by Vaccination in Condition of CD4+ T-cell Deficiency.
J. Virol. Epub ahead of print, 2008. [Journal]

7) Fukumoto R, Dundr M, Nicot C, Adams A, Valeri VW, Samelson LE, Franchini G.
Inhibition of TCR Signal Transduction and Viral Expression by the Linker for Activation of T Cells-Interacting p12I Protein of HTLV-1.
J Virol. 81: 9088-99, 2007. [Journal]

8) Hryniewicz A, Price DA, Moniuszko M, Boasso A, Edghill-Spano Y, West SM, Venzon D, Vaccari M, Tsai WP, Tryniszewska E, Nacsa J, Villinger F, Ansari AA, Trindade CJ, Morre M, Brooks D, Arlen P, Brown HJ, Kitchen CM, Zack JA, Douek DC, Shearer GM, Lewis MG, Koup RA, Franchini G.
Interleukin-15 but not interleukin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virusmac251-infected macaques.
J. Immunol. 178: 3492-504, 2007. [Journal]

9) von Gegerfelt AS, Rosati M, Alicea C, Valentin A, Roth P, Bear J, Franchini G, Albert PS, Bischofberger N, Boyer JD, Weiner DB, Markham P, Israel ZR, Eldridge JH, Pavlakis GN, Felber BK.
Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization.
J. Virol. 81: 1972-9, 2007. [Journal]

10) Boasso A, Vaccari M, Hryniewicz A, Fuchs D, Nacsa J, Cecchinato V, Andersson J, Franchini G, Shearer GM, Chougnet C.
Regulatory T cell markers, indoleamine (2,3)-dioxygenase and virus levels in spleen and gut during progressive SIV infection.
J Virol. 81: 11593-603, 2007. [Journal]

11) Petrovas C, Price DA, Mattapallil J, Ambrozak DR, Geldmacher C, Cecchinato V, Vaccari M, Tryniszewska E, Gostick E, Roederer M, Douek DC, Morgan SH, Davis SJ, Franchini G, Koup RA.
SIV-specific CD8+T-cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection.
Blood. 110: 928-36, 2007. [Journal]

12) Hryniewicz A, Boasso A, Edghill-Smith Y, Vaccari M, Fuchs D, Venzon D, Nacsa J, Betts MR, Tsai W, Heraud J, Beer B, Blanset D, Chougnet C, Lowy I, Shearer GM, Franchini G.
CTLA-4 blockade decreases TGF-{beta}, indoleamine 2,3- dioxygenase, and viral RNA expression in tissues of SIVmac251-infected macaques.
Blood. 108: 3834-42, 2006. [Journal]

13) Hel Z, Tsai WP, Tryniszewska E, Nacsa J, Markham PD, Lewis MG, Pavlakis GN, Felber BK, Tartaglia J, Franchini G.
Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes.
J Immunol. 176: 85-96, 2006. [Journal]

14) Heraud JM, Edghill-Smith Y, Ayala V, Kalisz I, Parrino J, Kalyanaraman VS, Manischewitz J, King LR, Hryniewicz A, Trindade CJ, Hassett M, Tsai WP, Venzon D, Nalca A, Vaccari M, Silvera P, Bray M, Graham BS, Golding H, Hooper JW, Franchini G.
Subunit Recombinant Vaccine Protects against Monkeypox.
J. Immunol. 177: 2552-64, 2006. [Journal]

15) Pal R, Venzon D, Santra S, Kalyanaraman VS, Montefiori DC, Hocker L, Hudacik L, Rose N, Nacsa J, Edghill-Smith Y, Moniuszko M, Hel Z, Belyakov IM, Berzofsky JA, Parks RW, Markham PD, Letvin NL, Tartaglia J, Franchini G.
Systemic Immunization with an ALVAC-HIV-1/Protein Boost Vaccine Strategy Protects Rhesus Macaques from CD4+ T-Cell Loss and Reduces both Systemic and Mucosal Simian-Human Immunodeficiency Virus SHIVKU2 RNA Levels.
J Virol. 80: 3732-42, 2006. [Journal]

16) Nacsa J, Edghill-Smith Y, Tsai WP, Venzon D, Tryniszewska E, Hryniewicz A, Moniuszko M, Kinter A, Smith KA, Franchini G.
Contrasting Effects of Low-Dose IL-2 on Vaccine-Boosted Simian Immunodeficiency Virus (SIV)-Specific CD4+ and CD8+ T Cells in Macaques Chronically Infected with SIVmac251.
J Immunol. 174: 1913-21, 2005. [Journal]

17) Nicot C, Harrod RL, Ciminale V, Franchini G.
Human T-cell leukemia/lymphoma virus type 1 nonstructural genes and their functions.
Oncogene. 24: 6026-34, 2005. [Journal]

18) Edghill-Smith Y, Bray M, Whitehouse CA, Miller D, Mucker E, Manischewitz J, King LR, Robert-Guroff M, Hryniewicz A, Venzon D, Meseda C, Weir J, Nalca A, Livingston V, Wells J, Lewis MG, Huggins J, Zwiers SH, Golding H, Franchini G.
Smallpox Vaccine Does Not Protect Macaqueswith AIDS from a Lethal MonkeypoxVirus Challenge.
J Infect Dis. 191: 372-81, 2005. [Journal]

19) Edghill-Smith Y, Golding H, Manischewitz J, King LR, Scott D, Bray M, Nalca A, Hooper JW, Whitehouse CA, Schmitz JE, Reimann KA, Franchini G.
Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus.
Nat Med. 11: 740-7, 2005. [Journal]

20) Vaccari M, Trindade CJ, Venzon D, Zanetti M, Franchini G.
Vaccine-Induced CD8+ Central Memory T Cells in Protection from Simian AIDS.
J Immunol. 175: 3502-7, 2005. [Journal]

21) Nicot C, Dundr M, Johnson JM, Fullen JR, Alonzo N, Fukumoto R, Princler GL, Derse D, Misteli T, Franchini G.
HTLV-1-encoded p30II is a post-transcriptional negative regulator of viral replication.
Nat Med. 10: 197-201, 2004. [Journal]

22) Edghill-Smith Y, Venzon D, Karpova T, McNally J, Nacsa J, Tsai WP, Tryniszewska E, Moniuszko M, Manischewitz J, King LR, Snodgrass SJ, Parrish J, Markham P, Sowers M, Martin D, Lewis MG, Berzofsky JA, Belyakov IM, Moss B, Tartaglia J, Bray M, Hirsch V, Golding H, Franchini G.
Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques.
J Infect Dis. 188: 1181-91, 2003. [Journal]

23) Franchini G, Nicot C, Johnson JM.
Seizing of T cells by human T-cell leukemia/lymphoma virus type 1.
Adv Cancer Res. 89: 69-132, 2003. [Journal]

24) Hel Z, Nacsa J, Tryniszewska E, Tsai WP, Parks RW, Montefiori DC, Felber BK, Tartaglia J, Pavlakis GN, Franchini G.
Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses.
J Immunol. 169: 4778-87, 2002. [Journal]

25) Tryniszewska E, Nacsa J, Lewis MG, Silvera P, Montefiori D, Venzon D, Hel Z, Parks RW, Moniuszko M, Tartaglia J, Smith KA, Franchini G.
Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy.
J Immunol. 169: 5347-57, 2002. [Journal]

26) Hel Z, Tsai WP, Thornton A, Nacsa J, Giuliani L, Tryniszewska E, Poudyal M, Venzon D, Wang X, Altman J, Watkins DI, Lu W, von Gegerfelt A, Felber BK, Tartaglia J, Pavlakis GN, Franchini G.
Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen.
J Immunol. 167: 7180-91, 2001. [Journal]

27) Hel Z, Venzon D, Poudyal M, Tsai WP, Giuliani L, Woodward R, Chougnet C, Shearer G, Altman JD, Watkins D, Bischofberger N, Abimiku A, Markham P, Tartaglia J, Franchini G.
Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques.
Nat Med. 6: 1140-6, 2000. [Journal]

28) Franchini G, Dundr M, Fullen J, inventor; DHHS, assignee.
HIV Tev Compositions And Methods Of Use.
Patent Pending, Filed in 2004. Application No. 11/364,873. Pending [Patent]

29) Franchini G, Nicot C, inventor; DHHS, assignee.
HTLV-I p3011 and p12I Proteins as Therapeutic Targets in HTLV-1 Infected Individ.
Patent Pending Application No. 60/404,580. Pending [Patent]

30) Franchini G, Hel Z, Shearer G, Tartaglia J, inventor; DHHS, assignee.
Immunotherapy In HIV Infected Persons Using Vaccines After Multi-drug Treatment.
Patent Pending, Filed in 1999. Application No. 10/048,072. Pending [Patent]

31) Franchini G, Tartaglia J, inventor; DHHS, assignee.
Immunotherapy Regimens In HIV-infected Patients.
Patent Pending, Filed in 2002. Application No. 10/513,257. Pending [Patent]

32) Franchini G, Hel Z, Tartaglia J, inventor; DHHS, assignee.
Novel Chimeric Rev, Tat, And Nef Antigens.
Patent Pending, Filed in 2000. Application No. 10/495,532. Pending [Patent]

33) Franchini G, Hooper J, inventor; DHHS, assignee.
Protein Vaccine Against Poxviruses.
Patent Pending, Filed in 2005. Application No. 11/523,867. Pending [Patent]

34) Franchini G, Wong-Staal F, Gallo R, inventor; DHHS, assignee.
Characterization of Replication Competent Human Immunodeficiency Type 2 Proviral Clone HIV-2.sub.SBL/ISY.
US Patent: 5,223,423. 1993. [Patent]

35) Paoletti E, Cox W, Franchini G, Gallo R, Tartaglia J, inventor; DHHS, assignee.
Immunodeficiency Recombinant Poxvirus.
US Patent: 6,596,279; 5,863,542; 5,494,807. 2003; 1999; 1996. [Patent]

36) Franchini G, Hel Z, Pavlakis G, Tartaglia J, inventor; DHHS, assignee.
Immunogenicity Using A Combination Of DNA And Vaccinia Virus Vector Vaccines.
US Patent: 7,094,408. 2006. [Patent]

37) Reitz, Jr. M, Franchini G, Markham P, Gallo R, Lori F, Popovic M, Gartner S, inventor; DHHS, assignee.
Molecular Clones of HIV-1 Viral Strains MH-ST1 and BA-L, and Uses Thereof.
US Patent: 5,576,000. 1996. [Patent]

38) Reitz, Jr. M, Franchini G, Markham P, Gallo R, Lori F, Popovic M, Gartner S, inventor; DHHS, assignee.
Molecular Clones of HIV-1 Viral Strains MN-ST1 and BA-L and Uses Thereof.
US Patent: 5,420,030. 1995. [Patent]

39) Reitz, Jr. M, Franchini G, Markham P, Gallo R, Lori F, Popovic M, Gartner S, inventor; DHHS, assignee.
Molecular Clones of HIV-1 Viral Strains MN-ST1 and BA-L, and Uses Thereof.
US Patent: 5,869,313. 1999. [Patent]

40) Paoletti E, Cox W, Franchini G, Gallo R, Tartaglia J, inventor; DHHS, assignee.
Recombinant Attenuated Alvac Canary Poxvirus Expression Vectors Containing Heterologous DNA Segments Encoding Lentiviral Gene Products.
US Patent: 5,766,598. 1998. [Patent]

This page was last updated on 11/25/2008.